methods for treating disease, for promoting lean growth, for treating or normalizing a dysbiotic microbiota in the gut, for increasing intestinal microbiota gene richness, for increasing number of intestinal microbiota phyla, for increasing short chain fatty acid production of the intestinal microbiota / metabolome, to increase bacterial numbers, to decrease bacterial numbers, defensin a, ss defensin, or a bioactive fragment thereof, and ss defensin and / or defensin and / or a glp-1 / glp-analog 1.

摘要

The present invention relates to methods for modulating the intestinal microbiota by administering one or more defensins and / or glp-1 / glp-1 analogs and methods for preventing or treating intestinal inflammation by orally administering one or more defensins. . glp-1 analogs such as liraglutide as well as mammalian and poultry alpha and beta defensins may cause a change in the composition of the microbiota and metabolome in the gut and thus may be used to treat or prevent intestinal inflammation, cancer. colorectal disease, metabolic syndrome, obesity, pre-diabetes and diabetes or as promoters of lean growth in meat production.